Tagitanlimab
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Tagitanlimab, covering 2025-08-07 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]